5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
ella O
is O
not O
indicated O
for O
termination O
of O
an O
existing O
pregnancy O
. O

Exclude O
pregnancy O
before O
administering O
. O

( O
5.1 O
) O
* O
Ectopic O
pregnancy O
: O
Women O
who O
become O
pregnant O
or O
complain O
of O
lower O
abdominal O
pain O
after O
taking O
ella O
should O
be O
evaluated O
for O
ectopic O
pregnancy O
. O

( O
5.2 O
) O
* O
Effect O
on O
menstrual O
cycle O
: O
ella O
may O
alter O
the O
next O
expected O
menses O
. O

If O
menses O
is O
delayed O
beyond O
1 O
week O
, O
pregnancy O
should O
be O
ruled O
out O
. O

( O
5.5 O
) O
* O
ella O
does O
not O
protect O
against O
STI/HIV O
. O

( O
5.6 O
) O
5.1 O
Existing O
Pregnancy O
ella O
is O
not O
indicated O
for O
termination O
of O
an O
existing O
pregnancy B-Not_AE_Candidate
. O

Pregnancy B-Not_AE_Candidate
should O
be O
excluded O
before O
prescribing O
ella O
. O

If O
pregnancy B-Not_AE_Candidate
can O
not O
be O
excluded O
on O
the O
basis O
of O
history O
and/or O
physical O
examination O
, O
pregnancy B-NonOSE_AE
testing I-NonOSE_AE
should O
be O
performed O
. O

A O
follow-up O
physical O
or O
pelvic O
examination O
is O
recommended O
if O
there O
is O
any O
doubt O
concerning O
the O
general O
health O
or O
pregnancy B-NonOSE_AE
status O
of O
any O
woman O
after O
taking O
ella O
. O

5.2 O
Ectopic O
Pregnancy O
A O
history O
of O
ectopic B-Not_AE_Candidate
pregnancy I-Not_AE_Candidate
is O
not O
a O
contraindication O
to O
use O
of O
this O
emergency O
contraceptive O
method O
. O

Healthcare O
providers O
, O
however O
, O
should O
consider O
the O
possibility O
of O
ectopic B-NonOSE_AE
pregnancy I-NonOSE_AE
in O
women O
who O
become O
pregnant B-NonOSE_AE
or O
complain O
of O
lower B-NonOSE_AE
abdominal I-NonOSE_AE
pain I-NonOSE_AE
after O
taking O
ella O
. O

A O
follow-up O
physical O
or O
pelvic O
examination O
is O
recommended O
if O
there O
is O
any O
doubt O
concerning O
the O
general O
health O
or O
pregnancy B-NonOSE_AE
status O
of O
any O
woman O
after O
taking O
ella O
. O

5.3 O
Repeated O
Use O
ella O
is O
for O
occasional O
use O
as O
an O
emergency B-Not_AE_Candidate
contraceptive I-Not_AE_Candidate
. O

It O
should O
not O
replace O
a O
regular O
method O
of O
contraception O
. O

Repeated O
use O
of O
ella O
within O
the O
same O
menstrual O
cycle O
is O
not O
recommended O
, O
as O
safety O
and O
efficacy O
of O
repeat O
use O
within O
the O
same O
cycle O
has O
not O
been O
evaluated O
. O

5.4 O
CYP3A4 O
Inducers O
A O
CYP3A4 O
inducer O
, O
rifampin O
, O
decreases O
the O
plasma O
concentration O
of O
ella O
significantly O
. O

Ella O
should O
not O
be O
administered O
with O
CYP3A4 O
inducers O
[ O
see O
Drug O
interactions O
( O
7.1 O
) O
and O
Pharmacokinetics O
( O
12.3 O
) O
] O
. O

5.5 O
Fertility O
Following O
Use O
A O
rapid O
return O
of O
fertility O
is O
likely O
following O
treatment O
with O
ella O
for O
emergency O
contraception O
; O
therefore O
, O
routine O
contraception O
should O
be O
continued O
or O
initiated O
as O
soon O
as O
possible O
following O
use O
of O
ella O
to O
ensure O
ongoing O
prevention O
of O
pregnancy B-NonOSE_AE
. O

While O
there O
are O
no O
data O
about O
use O
of O
ella O
with O
regular O
hormonal O
contraceptives O
, O
due O
to O
its O
high O
affinity O
binding O
to O
the O
progesterone O
receptor O
, O
use O
of O
ella O
may O
reduce O
the O
contraceptive O
action O
of O
regular O
hormonal O
contraceptive O
methods O
. O

Therefore O
, O
after O
use O
of O
ella O
, O
a O
reliable O
barrier O
method O
of O
contraception O
should O
be O
used O
with O
subsequent O
acts O
of O
intercourse O
that O
occur O
in O
that O
same O
menstrual O
cycle O
. O

5.6 O
Effect O
on O
Menstrual O
Cycle O
After O
ella O
intake O
, O
menses B-OSE_Labeled_AE
sometimes O
occur I-OSE_Labeled_AE
earlier O
or O
later I-OSE_Labeled_AE
than O
expected O
by O
a O
few O
days O
. O

In O
clinical O
trials O
, O
cycle O
length O
was O
increased O
by O
a O
mean O
of O
2.5 O
days O
but O
returned O
to O
normal O
in O
the O
subsequent O
cycle O
. O

Seven O
percent O
of O
subjects O
reported O
menses B-OSE_Labeled_AE
occurring O
more O
than O
7 O
days O
earlier I-OSE_Labeled_AE
than O
expected O
, O
and O
19 O
% O
reported O
a O
delay O
of O
more O
than O
7 O
days O
. O

If O
there O
is O
a O
delay B-NonOSE_AE
in O
the O
onset O
of O
expected O
menses I-NonOSE_AE
beyond O
1 O
week O
, O
rule O
out O
pregnancy B-Not_AE_Candidate
. O

Nine O
percent O
of O
women O
studied O
reported O
intermenstrual B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
after O
use O
of O
ella O
. O

5.7 O
Sexually O
Transmitted O
Infections/HIV O
ella O
does O
not O
protect O
against O
HIV B-Not_AE_Candidate
infection I-Not_AE_Candidate
( I-Not_AE_Candidate
AIDS I-Not_AE_Candidate
) O
or O
other O
sexually B-Not_AE_Candidate
transmitted I-Not_AE_Candidate
infections I-Not_AE_Candidate
( I-Not_AE_Candidate
STIs I-Not_AE_Candidate
) O
. O

